Met, metastasis, motility and more

By C. Birchmeier, W. Birchmeier, E. Gherardi, G. Woude. Nature reviews. Molecular cell biology, 2003

2,612 citations recorded by the source corpus.

Subfields: Hepatology, Immunology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/09b3a3a9e41d9bcfe74724ee68e9c054a544a5a3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Ming-Sound Tsao
2. S. Organ

In Immunology

1. J. Campisi
2. Gerhard Christofori
3. H. Moses
4. M. Demaria
5. Adam Freund
6. C. Patil
7. J. Kirkland
8. Jesús Gil

In Pathology and Forensic Medicine

1. W. Birchmeier
2. H. Moses

Citations in the corpus

• Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth (2011, background): “gastric, pancreatic, prostate, ovarian, breast, and lung cancers, and is often correlated with poor prognosis (1, 7).”
• Drug development of MET inhibitors: targeting oncogene addiction and expedience (2008, background): “jpg" NDATA ITEM> ]> The MET tyrosine kinase is a cell surface receptor for hepatocyte growth factor ( HGF , also known as scatter factor), a pleiotropic cytokine that conveys a unique combination of pro-migratory, anti-apoptotic and mitogenic signal”
• New signals from the invasive front (2006, background): “HGF, which is produced mainly by stromal cells, and the c-Met receptor tyrosine kinase (RTK), its cognate receptor on tumour cells, are key mediators of invasive growth during embryonic development and tumour progressio”
• The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. (2009, background): “HGF/c-Met signalling is classically associated with loss of cell-cell contact (or scattering) and invasive growth [110].”
• Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy (2012, neutral): “tion, and invasion [65, 66].”
• Tyrosine residues 654 and 670 in β-catenin are crucial in regulation of Met–β-catenin interactions (2006, neutral): “for epithelial cells [15,16].”
• The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression (2010, background): “Epithelial cells—In pancreatic cancer, hepatocyte growth factor (HGF), and to a lesser degree basic fibroblast growth factor (bFGF), promotes cancer cell invasion in culture and can potentially drive cancer dissemination in vivo (117, 130).”
• Stromal fibroblasts in cancer initiation and progression (2004, result): “Several reports support the transforming ability of HGF (ref”
• An overview of the c-MET signaling pathway (2011, background): “…expression of the c-MET RTK and its ligand, hepatocyte growth factor (HGF), has been observed in tumor biopsies of most solid tumors and c-MET signaling has been documented in a wide range of human malignancies [Peruzzi and Bottaro, 2006; Birchmeier et al. 2003; Comoglio and Trusolino, 2002].”
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. (2008, background): “in a wide variety of cells, including mitogenic, motogenic, morphogenic, and antiapoptotic activities (17, 18).”
• Developmental cell biology: Eph receptor signalling casts a wide net on cell behaviour (2005, background): “The hepatocyte growth factor (HGF) receptor tyrosine kinase induces the formation of cellular protrusions that elongate and branch into tubular structures, such as the lung airways and kidney tubule”
• Balancing cell adhesion and Wnt signaling, the key role of β-catenin (2006, background): “In addition, these changes correlate with poor prognosis in tumors [37, 38 ,46].”
• Senescent cells as a source of inflammatory factors for tumor progression (2010, background): “In pancreatic cancer, hepatocyte growth factor (HGF), and to a lesser degree bFGF, promote cancer cell invasion in culture and potentially can drive cancer dissemination in vivo [107, 121].”